Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Left Atrial Function in HFmrEF and HFpEF
NCT05600387Phase 4Unknown
- Start
- Nov 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in heart failure with mildly reduced ejection fraction (HFmrEF), heart failure with preserved ejection fraction (HFpEF). Status: unknown.
02
Drugs
empagliflozin
03
Conditions
heart failure with mildly reduced ejection fraction (HFmrEF)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05600387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05600387.